Literature DB >> 24691683

Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae.

B Pilmis1, P Parize, J R Zahar, O Lortholary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24691683     DOI： 10.1007/s10096-014-2094-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  11 in total

Review 1.  Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).

Authors:  D L Paterson
Journal:  Clin Microbiol Infect       Date:  2000-09       Impact factor: 8.067

Review 2.  Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact.

Authors:  Gerhard F Weldhagen; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 3.  Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe.

Authors:  R Cantón; M Akóva; Y Carmeli; C G Giske; Y Glupczynski; M Gniadkowski; D M Livermore; V Miriagou; T Naas; G M Rossolini; Ø Samuelsen; H Seifert; N Woodford; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2012-05       Impact factor: 8.067

Review 4.  [Extension of beta-lactamases producing bacteria is a worldwide concern].

Authors:  Jean-Ralph Zahar; Emmanuelle Bille; David Schnell; Fanny Lanternier; Frédéric Mechai; Virginie Masse; Xavier Nassif; Olivier Lortholary
Journal:  Med Sci (Paris)       Date:  2009-11       Impact factor: 0.818

5.  Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.

Authors:  Raphaël Lepeule; Etienne Ruppé; Patrick Le; Laurent Massias; Françoise Chau; Amandine Nucci; Agnès Lefort; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.191

6.  Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.

Authors:  S Meier; R Weber; R Zbinden; C Ruef; B Hasse
Journal:  Infection       Date:  2011-06-25       Impact factor: 3.553

7.  Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009-2010.

Authors:  Daryl J Hoban; Lindsay E Nicolle; Stephen Hawser; Samuel Bouchillon; Robert Badal
Journal:  Diagn Microbiol Infect Dis       Date:  2011-08       Impact factor: 2.803

8.  Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome.

Authors:  Yun-Kyung Kim; Hyunjoo Pai; Hoan-Jong Lee; Su-Eun Park; Eun-Hwa Choi; Jungmin Kim; Je-Hak Kim; Eui-Chong Kim
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

9.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.

Authors:  D L Paterson; L Mulazimoglu; J M Casellas; W C Ko; H Goossens; A Von Gottberg; S Mohapatra; G M Trenholme; K P Klugman; J G McCormack; V L Yu
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

10.  Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers.

Authors:  Mathias W R Pletz; Mareike Rau; Juergen Bulitta; Andres De Roux; Olaf Burkhardt; Guido Kruse; Michael Kurowski; Carl E Nord; Hartmut Lode
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191
View more
  11 in total

1.  Management of bloodstream infections by infection specialists in France and Germany: a cross-sectional survey.

Authors:  Kévin Diallo; Winfried V Kern; Katja de With; Amandine Luc; Nathalie Thilly; Céline Pulcini
Journal:  Infection       Date:  2018-02-03       Impact factor: 3.553

Review 2.  The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Authors:  Pranita D Tamma; Jesus Rodriguez-Bano
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

3.  Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia.

Authors:  Yasufumi Matsumura; Masaki Yamamoto; Miki Nagao; Toshiaki Komori; Naohisa Fujita; Akihiko Hayashi; Tsunehiro Shimizu; Harumi Watanabe; Shoichi Doi; Michio Tanaka; Shunji Takakura; Satoshi Ichiyama
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

Review 4.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

5.  Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.

Authors:  O Senard; M Lafaurie; P Lesprit; Y Nguyen; X Lescure; A Therby; V Fihman; N Oubaya; R Lepeule
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-11       Impact factor: 3.267

6.  Is Cefoxitin a Carbapenem Sparing Agent in the Management of Urinary Tract Infections Caused by ESBL Producing Enterobacterales?

Authors:  Wasim S El Nekidy; Manal M Abdelsalam; Ahmad R Nusair; Rania El Lababidi; Ruba Z Dajani; Terrence J Lee St John; Islam M Ghazi
Journal:  Hosp Pharm       Date:  2021-12-30

7.  Modelling of the transmission dynamics of carbapenem-resistant Klebsiella pneumoniae in hospitals and design of control strategies.

Authors:  Suttikiat Changruenngam; Charin Modchang; Dominique J Bicout
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.996

8.  Community-Onset Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Invasive Infections in Children in a University Hospital in France.

Authors:  Julie Toubiana; Sandra Timsit; Agnès Ferroni; Marie Grasseau; Xavier Nassif; Olivier Lortholary; Jean-Ralph Zahar; Martin Chalumeau
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

Review 9.  Piperacillin-tazobactam as alternative to carbapenems for ICU patients.

Authors:  Benoit Pilmis; Vincent Jullien; Alexis Tabah; Jean-Ralph Zahar; Christian Brun-Buisson
Journal:  Ann Intensive Care       Date:  2017-11-10       Impact factor: 6.925

Review 10.  Carbapenem-Sparing Strategies for ESBL Producers: When and How.

Authors:  Ilias Karaiskos; Helen Giamarellou
Journal:  Antibiotics (Basel)       Date:  2020-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.